Literature DB >> 8531100

Characterization of 5-lipoxygenase inhibitors in biochemical and functional in vivo assays.

W G Smith1, A F Shaffer, J L Currie, J M Thompson, S Kim, T Rao, P C Isakson.   

Abstract

Several potent and selective inhibitors of 5-lipoxygenase (5-LO) have been recently developed with excellent activity in certain in vivo assays of leukotriene production. The efficacy of three such inhibitors that have been in clinical trials (zileuton, A-78773 and ZD2138) were evaluated in: 1) ex vivo whole blood assay, 2) dermal Arthus reaction, and 3) functional airway response. In addition, a model of eicosanoid production in rat lung was developed that provides a simple assay for evaluation of the biochemical efficacy of 5-LO inhibitors in the lung. Bronchoalveolar lavage of rat lung with calcium ionophore A23187 resulted in rapid and robust production of PGE2, 6-keto-PGF1 alpha, thromboxane (TxB2), and leukotriene B4 (LTB4). Supplementation of lavage fluid with archidonic acid markedly augmented production of all eicosanoids except LTB4. All three inhibitors were potent and selective blockers of LTB4 production in the ex vivo whole blood assay and in the dermal Arthus reaction. In contrast, higher doses of inhibitor were needed to block LTB4 production in the rat lung lavage model than were needed to block ex vivo whole blood LTB4 production when both end points were measured in the same animal. Similarly, zileuton and A-78733 were less effective in suppressing the functional airway response to antigen in sensitized guinea pigs, whereas both inhibitors were effective in suppressing LTB4 production in the ex vivo whole blood assay. These results demonstrate that different 5-LO inhibitors have markedly distinct efficacy for inhibition of leukotriene production, depending on the animal model.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8531100

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  Pharmacological analysis of cyclooxygenase-1 in inflammation.

Authors:  C J Smith; Y Zhang; C M Koboldt; J Muhammad; B S Zweifel; A Shaffer; J J Talley; J L Masferrer; K Seibert; P C Isakson
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

2.  Inhibition of immune-complex mediated dermal inflammation in rats following either oral or topical administration of a small molecule C5a receptor antagonist.

Authors:  A J Strachan; I A Shiels; R C Reid; D P Fairlie; S M Taylor
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

3.  Molecular pharmacological profile of the nonredox-type 5-lipoxygenase inhibitor CJ-13,610.

Authors:  Lutz Fischer; Dieter Steinhilber; Oliver Werz
Journal:  Br J Pharmacol       Date:  2004-06-14       Impact factor: 8.739

4.  Evidence that 5-lipoxygenase and acetylated cyclooxygenase 2-derived eicosanoids regulate leukocyte-endothelial adherence in response to aspirin.

Authors:  Stefano Fiorucci; Eleonora Distrutti; Andrea Mencarelli; Antonio Morelli; Stefan A Laufor; Giuseppe Cirino; John L Wallace
Journal:  Br J Pharmacol       Date:  2003-08       Impact factor: 8.739

5.  The molecular mechanism of the inhibition by licofelone of the biosynthesis of 5-lipoxygenase products.

Authors:  L Fischer; M Hornig; C Pergola; N Meindl; L Franke; Y Tanrikulu; G Dodt; G Schneider; D Steinhilber; O Werz
Journal:  Br J Pharmacol       Date:  2007-08-20       Impact factor: 8.739

6.  Multi-Walled Carbon Nanotubes Augment Allergic Airway Eosinophilic Inflammation by Promoting Cysteinyl Leukotriene Production.

Authors:  Sophia Carvalho; Maria Ferrini; Lou Herritt; Andrij Holian; Zeina Jaffar; Kevan Roberts
Journal:  Front Pharmacol       Date:  2018-06-05       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.